Fulgent Genetics Return on Equity

Fulgent Genetics (FLGT) currently reports a ROE of -8.42%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Fulgent Genetics's ROE history and peer comparisons.

Fulgent Genetics's ROE of -8.42% is lower than the Healthcare sector average of 29.33%. That is roughly 128.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Fulgent Genetics's current -8.42% should be judged against Healthcare norms (sector average: 29.33%) and against FLGT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -8.42%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Fulgent Genetics, and consider following FLGT for alerts when major investors trade the stock.

Fulgent Genetics is classified in the Healthcare sector. On ROE, it currently shows -8.42% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FLGT with unrelated industries.